Here's Why Amgen Shares Are Worth $117 To $126 Today
Amgen shares have had an impressive run this year, outpacing the S&P 500 by about 6%. Nevertheless, despite outpacing the broader market, Amgen has only matched the Health Care Sector Select Sector SPDR and has greatly lagged its large-cap biotech peers.
Fri May 17, 2013
Amgen PT Raised to $120.00 at Credit Suisse
The firm currently has a "neutral" rating on the stock. Shares of Amgen traded up 0.63% during mid-day trading on Friday, hitting $105.63. Amgen has a 52 week low of $67.61 and a 52 week high of $114.95. The stock's 50-day moving average is currently $100.6. The company has a market cap of $79.220 billion and a P/E ratio of 17.77. Amgen last ... (more)
Wed May 15, 2013
Applied Clinical Trials
New Analyses Identify Predictive Biomarkers For Vectibix?...
Biomarker Analysis From Phase 3 PRIME Study and Phase 2 PEAK Study Link Additional RAS Gene Mutations to Vectibix Clinical Response Biomarker Analysis From Phase 3 PRIME Study and Phase 2 PEAK Study Link Additional RAS Gene Mutations to Vectibix Clinical Response /PRNewswire/ -- Amgen today announced results from three analyses of Vectibix in ... (more)
Applied Clinical Trials
Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
"The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers," said , M.D., executive vice president of Research and Development at Amgen.
Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest...
Biogen Idec is estimated to post earnings of $2.07 per share in the September quarter.
Mon May 13, 2013
The Week in Review: Sagent Pharmaceuticals, Inc. Buys Out China JV Partner for $25 Million
May 11, 2013 -- Sagent Pharma, a US generic injectible drugmaker, will pay $25 million to acquire its partner's 50% interest in a China manufacturing JV; ScinoPharm Taiwan and Coland Holdings formed a partnership to bring generic oncology drugs to mainland China; Zhejiang Huahai Pharma joined with Oncobiologics to develop and make biosimilars of ... (more)
Bay City Capital Expands Team With the Addition of David Beier, JD
Bay City Capital, a leading venture capital firm focused on early-stage to growth equity investments in the life sciences, today announced the addition of David Beier, JD as Managing Director.
Customer Interaction Solutions
RBCC Partner n3D Signs U.S. Distribution Agreement
Rainbow Coral Corp. received word this week that the revolutionary technology developed by its partner, Nano3D Biosciences , is set to begin penetrating the U.S. marketplace.
Sun May 12, 2013
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
This article is the second in a three part series about Array BioPharma Inc. , a biopharmaceutical company that is developing small molecule drug candidates for the treatment of cancers and other diseases.
China Biotech In Review: Sagent Buys Out China JV Partner For $25 Million
Sagent Pharmaceuticals , a Chicago-area maker of generic injectible drugs, will acquire its partner's 50% interest in a China JV for $25 million .
Sat May 11, 2013
Patrick Dempsey's ride to fight cancer
Although most people know actor Patrick Dempsey as Dr. Derek Shepherd on ABC's "Grey's Anatomy," one of his biggest recurring roles is as an ambassador for Breakaway from Cancer, a "national initiative affiliated with pharmaceutical company Amgen, Inc.
Strategy Behind Our Success, We Get in Early: PSX, AMGN, MPC and BAX
Give yourself an advantage in today's market. In order to become successful, you need to have information as it happens and understand how it plays out into future stock price.
Thu May 09, 2013
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Amgen and Zhejiang Beta Pharma Co., Ltd. today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix in the Chinese market.
Amgen Forms China Joint Venture With Zhejiang Beta Pharma
Amgen Inc. will form a joint venture with Chinese pharmaceutical firm Zhejiang Beta Pharma Co.
Technical Bull Stock Alert: Amgen, Inc. (AMGN), Target 112
The online StockConsultant latest screen has found a biotechnology medicines company Amgen, Inc.
Wed May 08, 2013
Amgen Chased By The Bubble
There are two relatively heated debates that bear directly on Amgen and its stock.
Keryx: A Small Biotech With Many Catalysts
KERX ) almost tripled in price in the final four days of January, following the January 28th early-morning release of top-line data from a clinical trial assessing its lead new-drug prospect Zerenex in the treatment of patients with ESRD on dialysis; the price reached a high of $9.98 on the 31st, compared with the stock's 52-week low of $1.65 last ... (more)
Tue May 07, 2013
Applied Clinical Trials
Amgen Announces Top-Line Results of Vectibix? (panitumumab) Phase 3...
Amgen Announces Top-Line Results of Vectibix? Phase 3 Head-to-Head Study Against Erbitux? in Metastatic Colorectal Cancer Amgen Announces Top-Line Results of Vectibix Phase 3 Head-to-Head Study Against Erbitux in Metastatic Colorectal Cancer /PRNewswire/ -- Amgen today announced that the Phase 3 head-to-head ASPECCT trial evaluating Vectibix versus ... (more)
Affymax Could Be The Best Reversal Play For 2013
Rewind to 2012, Affymax was a favorite and top performing biotech stock for 2012.
X Factor: 5 Stocks Reaching Their Ex-Dividend Date on May 14
Many stocks will reach their ex-dividend date next Tuesday, which is significant for investors as the seller of the stock on that date, not the buyer, receives the most recent dividend.